Skip to search formSkip to main contentSkip to account menu

SGLT2 Inhibitor

Any inhibitor of the sodium-glucose co-transporter subtype 2 (SGLT2) with antihyperglycemic activity. By binding to and blocking SGLT2, these… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Qtern is a new fixed‐dose combination of the DPP‐4 inhibitor saxagliptin with the SGLT2 inhibitor dapagliflozin for the control… 
2015
2015
Sodium-glucose cotransporter 2 (SGLT2) is expressed in the proximal tubule of kidney and mediates reabsorption of approximately… 
2015
2015
Title: This is the case of a patient with Euglycemic Diabetic Ketoacidosis (euDKA), ascites, poor nutrition and diabetes mellitus… 
2015
2015
SGLT2 is a low affinity, high capacity glucose co-transporter, almost exclusively expressed in the kidney cortex. Inhibition of… 
2014
2014
Empagliflozin is agent of new antidiabetic drugs that cause glycosuria blocking the glucose reuptake in the proxi-mal tubule. The… 
2012
2012
본 발명은 환자에게 SGLT2 억제제를 투여함을 포함하는, 신경이완제로 치료하여 환자에서 유도된 대사 장애를 예방하거나, 상기 대사 장애의 진행을 완화시키거나, 상기 대사 장애를 지연시키거나, 치료하기 위한 방법에 관한 것이다. 
2010
2010
Total synthesis of SGLT2 inhibitor,Dapagliflozin,was achieved in a total yield of 34.5% starting from commercially available 5…